Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):435-42. doi: 10.1089/dia.2010.0184. Epub 2011 Feb 28.

PMID:
21355718
2.

Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.

Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hövelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):443-50. doi: 10.1089/dia.2010.0183. Epub 2011 Feb 28.

PMID:
21355716
3.

Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs.

Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ.

Pharm Res. 2011 Jan;28(1):107-16. doi: 10.1007/s11095-010-0123-9. Epub 2010 Mar 31.

PMID:
20354765
4.

A genetic linkage map of Venturia inaequalis, the causal agent of apple scab.

Xu X, Roberts T, Barbara D, Harvey NG, Gao L, Sargent DJ.

BMC Res Notes. 2009 Aug 18;2:163. doi: 10.1186/1756-0500-2-163.

5.

Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.

Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG.

Vaccine. 2007 Dec 17;25(52):8833-42. Epub 2007 Oct 29.

PMID:
18023942
6.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3. Epub 2007 May 13.

PMID:
17375001
7.

Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines.

Alarcon JB, Hartley AW, Harvey NG, Mikszta JA.

Clin Vaccine Immunol. 2007 Apr;14(4):375-81. Epub 2007 Feb 28.

8.

Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.

Mikszta JA, Dekker JP 3rd, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CJ, Ulrich RG.

Infect Immun. 2006 Dec;74(12):6806-10. Epub 2006 Oct 9.

9.

Anthrax vaccine powder formulations for nasal mucosal delivery.

Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ.

J Pharm Sci. 2006 Jan;95(1):80-96.

PMID:
16315230
10.

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker JP 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M, Jiang G, Mar K, Saikh KU, Stiles BG, Roy CJ, Ulrich RG, Harvey NG.

J Infect Dis. 2005 Jan 15;191(2):278-88. Epub 2004 Dec 15.

PMID:
15609239
11.

Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery.

Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG.

Nat Med. 2002 Apr;8(4):415-9.

PMID:
11927950
12.

Chemical bond-making, bond-breaking, and electron transfer in solution.

Arnett EM, Amarnath K, Harvey NG, Cheng JP.

Science. 1990 Jan 26;247(4941):423-30.

PMID:
17788608

Supplemental Content

Loading ...
Support Center